Last mentioned: Mar 23, 2026
Merger Reports
Reports surface regarding potential merger discussions between Estée Lauder and Puig.
Insider Selling
President and another insider report share sales in regulatory filings.
Insider Selling
President and another insider sell a combined 33,157 shares.
Analyst Downgrade
Wall Street Zen cuts ALHC rating to Hold.
Analyst Downgrade
Wall Street Zen cuts ALHC rating to Hold.
Analyst Upgrade
Baird raises Zions Bancorporation to a Buy-equivalent rating.
Offering Priced
Secondary offering is priced at $19.46 per share.
Secondary Offering
Company prices 13.2M shares at $19.46 to raise capital.
Secondary Offering Announced
Company announces intent to sell 13.2 million shares to raise capital.
Expected Q4 Earnings Call
Management is anticipated to provide final 2025 figures and formal guidance for the 2026 fiscal year.
Q4 Earnings Report
Alignment Healthcare reports a declining net loss for the fourth quarter of 2025.
Q4 Earnings Report
Alignment Healthcare reports declining losses and operational growth.
Earnings Preview Release
FinancialContent and other market trackers highlight ALHC as a key stock to watch ahead of Q4 reporting.
Agency Shift
Estée Lauder appoints WPP as its global media agency partner.
M&A Strategy
Estée Lauder CEO expresses openness to strategic acquisitions to aid turnaround.
Baird Model Update
Analysts at Baird set a bullish $59 price target for ALHC, signaling high confidence in the tech-enabled MA model.
Estée Lauder is reportedly in strategic merger discussions with Spanish beauty giant Puig as part of an aggressive turnaround plan. Meanwhile, Zions Bancorporation and Boreal Carbon Corp are drawing significant investor attention following analyst upgrades and shifting sentiment in environmental markets.
Alignment Healthcare's President and another insider divested over 33,000 shares in mid-March, following a massive secondary offering and a rating downgrade. The sales come as the Medicare Advantage provider reports narrowing losses but faces a shift in analyst sentiment from 'Buy' to 'Hold.'
Alignment Healthcare (NASDAQ: ALHC) has reported significant insider selling, including a 29,113-share disposal by its President, shortly after a major secondary offering. These transactions occur as the company navigates a shift in analyst sentiment and a challenging regulatory environment for Medicare Advantage providers.
Alignment Healthcare (ALHC) is set to report its fourth-quarter results, with investors focusing on membership growth and the medical loss ratio (MLR) within its tech-enabled Medicare Advantage platform. As the MA market faces regulatory headwinds, ALHC's ability to maintain clinical outcomes through its proprietary AVA software remains a critical differentiator.